3,792 Shares in STERIS plc $STE Purchased by Inceptionr LLC

Inceptionr LLC acquired a new stake in STERIS plc (NYSE:STE) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 3,792 shares of the medical equipment provider’s stock, valued at approximately $839,000.

A number of other large investors also recently bought and sold shares of the stock. Trust Co. of Vermont increased its position in shares of STERIS by 30.2% during the fourth quarter. Trust Co. of Vermont now owns 164 shares of the medical equipment provider’s stock valued at $42,000 after acquiring an additional 38 shares during the last quarter. Bailard Inc. increased its holdings in STERIS by 3.5% in the 4th quarter. Bailard Inc. now owns 1,118 shares of the medical equipment provider’s stock valued at $283,000 after purchasing an additional 38 shares during the last quarter. Geneos Wealth Management Inc. raised its position in STERIS by 34.9% in the second quarter. Geneos Wealth Management Inc. now owns 174 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 45 shares during the period. Ascent Group LLC raised its position in STERIS by 4.9% in the fourth quarter. Ascent Group LLC now owns 1,009 shares of the medical equipment provider’s stock valued at $256,000 after purchasing an additional 47 shares during the period. Finally, Clear Harbor Asset Management LLC lifted its stake in STERIS by 3.8% during the fourth quarter. Clear Harbor Asset Management LLC now owns 1,350 shares of the medical equipment provider’s stock worth $342,000 after purchasing an additional 50 shares in the last quarter. Institutional investors and hedge funds own 94.69% of the company’s stock.

STERIS Price Performance

Shares of NYSE STE opened at $214.16 on Friday. The stock’s 50-day moving average is $211.69 and its two-hundred day moving average is $227.60. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. STERIS plc has a 1-year low of $195.14 and a 1-year high of $269.44. The company has a market cap of $20.87 billion, a price-to-earnings ratio of 27.01 and a beta of 0.92.

STERIS (NYSE:STE) last announced its quarterly earnings data on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a net margin of 13.18% and a return on equity of 14.15%. The company had revenue of $1.59 billion during the quarter, compared to analysts’ expectations of $1.59 billion. During the same quarter in the previous year, the business posted $2.74 EPS. The business’s quarterly revenue was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts forecast that STERIS plc will post 11.18 EPS for the current fiscal year.

STERIS Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, June 26th. Investors of record on Monday, June 8th were paid a $0.63 dividend. The ex-dividend date was Monday, June 8th. This represents a $2.52 dividend on an annualized basis and a yield of 1.2%. STERIS’s payout ratio is currently 31.78%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Wall Street Zen lowered STERIS from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 6th. Weiss Ratings downgraded STERIS from a “hold (c+)” rating to a “hold (c)” rating in a report on Wednesday, May 27th. KeyCorp decreased their target price on STERIS from $291.00 to $269.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Finally, Piper Sandler restated an “overweight” rating and set a $270.00 target price on shares of STERIS in a report on Thursday, May 21st. Three analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $278.00.

Insider Buying and Selling

In other STERIS news, CEO Daniel A. Carestio sold 3,054 shares of the business’s stock in a transaction that occurred on Thursday, June 4th. The shares were sold at an average price of $214.64, for a total transaction of $655,510.56. Following the completion of the transaction, the chief executive officer owned 65,021 shares in the company, valued at $13,956,107.44. The trade was a 4.49% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP John Adam Zangerle sold 1,419 shares of the business’s stock in a transaction that occurred on Monday, June 15th. The stock was sold at an average price of $209.28, for a total transaction of $296,968.32. Following the transaction, the vice president owned 35,259 shares of the company’s stock, valued at $7,379,003.52. This trade represents a 3.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 7,328 shares of company stock worth $1,554,051 over the last 90 days. 1.12% of the stock is owned by insiders.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.